Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Rosing

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
Biochemistry|May 12, 2004
Functional properties of recombinant factor V mutated in a potential calcium-binding siteKristoffer W Sørensen, Gerry A F Nicolaes, Bruno O Villoutreix, et al.
The Journal of Biological Chemistry|December 9, 2003
Factor Va is inactivated by activated protein C in the absence of cleavage sites at Arg-306, Arg-506, and Arg-679Marijn van der Neut Kolfschoten, Richard J Dirven, Hans L Vos, et al.
The Journal of Biological Chemistry|May 21, 2010
Inhibition of thrombin formation by active site mutated (S360A) activated protein CGerry A F Nicolaes, Paul E Bock, Kenneth Segers, et al.
Blood|June 22, 2014
Fibrinogen γ' increases the sensitivity to activated protein C in normal and factor V Leiden plasmaFarida Omarova, Shirley Uitte de Willige, Paolo Simioni, et al.
Contraception|September 21, 2020
Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parametersJonathan Douxfils, Christine Klipping, Ingrid Duijkers, et al.
European Journal of Biochemistry|June 23, 2004
Altered inactivation pathway of factor Va by activated protein C in the presence of heparinGerry A F Nicolaes, Kristoffer W Sørensen, Ute Friedrich, et al.
Thrombosis and Haemostasis|November 10, 2019
Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFPIαPeter van Doorn, Jan Rosing, Elena Campello, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 25, 2007
Design of protein membrane interaction inhibitors by virtual ligand screening, proof of concept with the C2 domain of factor VKenneth Segers, Olivier Sperandio, Markus Sack, et al.
Thrombosis and Haemostasis|April 2, 2002
Effects of (pre-)analytical variables on activated protein C resistance determined via a thrombin generation-based assayJoyce Curvers, M Christella, L G D Thomassen, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 29, 2006
Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal womenMajoie Hemelaar, Jan Rosing, Peter Kenemans, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
Biochemistry|May 12, 2004
Functional properties of recombinant factor V mutated in a potential calcium-binding siteKristoffer W Sørensen, Gerry A F Nicolaes, Bruno O Villoutreix, et al.
The Journal of Biological Chemistry|December 9, 2003
Factor Va is inactivated by activated protein C in the absence of cleavage sites at Arg-306, Arg-506, and Arg-679Marijn van der Neut Kolfschoten, Richard J Dirven, Hans L Vos, et al.
The Journal of Biological Chemistry|May 21, 2010
Inhibition of thrombin formation by active site mutated (S360A) activated protein CGerry A F Nicolaes, Paul E Bock, Kenneth Segers, et al.
Blood|June 22, 2014
Fibrinogen γ' increases the sensitivity to activated protein C in normal and factor V Leiden plasmaFarida Omarova, Shirley Uitte de Willige, Paolo Simioni, et al.
Contraception|September 21, 2020
Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parametersJonathan Douxfils, Christine Klipping, Ingrid Duijkers, et al.
European Journal of Biochemistry|June 23, 2004
Altered inactivation pathway of factor Va by activated protein C in the presence of heparinGerry A F Nicolaes, Kristoffer W Sørensen, Ute Friedrich, et al.
Thrombosis and Haemostasis|November 10, 2019
Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFPIαPeter van Doorn, Jan Rosing, Elena Campello, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 25, 2007
Design of protein membrane interaction inhibitors by virtual ligand screening, proof of concept with the C2 domain of factor VKenneth Segers, Olivier Sperandio, Markus Sack, et al.
Thrombosis and Haemostasis|April 2, 2002
Effects of (pre-)analytical variables on activated protein C resistance determined via a thrombin generation-based assayJoyce Curvers, M Christella, L G D Thomassen, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 29, 2006
Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal womenMajoie Hemelaar, Jan Rosing, Peter Kenemans, et al.
Pageof 8